RUNX2 and osteosarcoma: Modulation of NNMT-SIRT1 interactions, optimization of combination therapies, and targeted inhibition of RUNX2-driven signaling pathways could serve as valuable strategies to enhance treatment efficacy and overcome chemoresistance in osteosarcoma.